<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet href="https://www.accessdata.fda.gov/spl/stylesheet/spl.xsl" type="text/xsl"?>
<document xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="urn:hl7-org:v3" xsi:schemaLocation="urn:hl7-org:v3 https://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="300b51d0-8fcb-24ef-e063-6294a90ad2b9"/>
   <code code="34391-3" codeSystem="2.16.840.1.113883.6.1" displayName="HUMAN PRESCRIPTION DRUG LABEL"/>
   <title>Metronidazole
 <br/>
Gel USP, 0.75%
</title>
   <effectiveTime value="20250311"/>
   <setId root="300b51d0-8fca-24ef-e063-6294a90ad2b9"/>
   <versionNumber value="1"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id root="1.3.6.1.4.1.519.1" extension="828374897"/>
            <name>Redpharm Drug</name>
            <assignedEntity>
               <assignedOrganization>
                  <assignedEntity>
                     <assignedOrganization>
                        <id root="1.3.6.1.4.1.519.1" extension="828374897"/>
                        <name>Redpharm Drug</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C73606" displayName="repack" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="67296-2121" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
               </assignedOrganization>
            </assignedEntity>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section>
               <id root="300b6c83-4663-2668-e063-6394a90a4c35"/>
               <code code="48780-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL product data elements section"/>
               <effectiveTime value="20250311"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="67296-2121" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Metronidazole</name>
                        <formCode code="C42934" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="GEL"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>metronidazole</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <asEquivalentEntity classCode="EQUIV">
                           <code code="C64637" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <definingMaterialKind>
                              <code code="51672-4116" codeSystem="2.16.840.1.113883.6.69"/>
                           </definingMaterialKind>
                        </asEquivalentEntity>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="4Q93RCW27E" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>CARBOMER HOMOPOLYMER TYPE C (ALLYL PENTAERYTHRITOL CROSSLINKED)</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="7FLD91C86K" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>EDETATE DISODIUM</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="A2I8C7HI9T" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>METHYLPARABEN</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="6DC9Q167V3" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>PROPYLENE GLYCOL</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="Z8IX2SC1OH" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>PROPYLPARABEN</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="059QF0KO0R" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>WATER</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="55X04QC32I" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM HYDROXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="7.5"/>
                              <denominator unit="g" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="140QMO216E" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>METRONIDAZOLE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="140QMO216E" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>METRONIDAZOLE</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator value="45" unit="g"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C42794" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TUBE"/>
                              <asContent>
                                 <quantity>
                                    <numerator value="1" unit="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="67296-2121-4" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20060718"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="ANDA077819" root="2.16.840.1.113883.3.150"/>
                           <code code="C73584" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20060718"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48330" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="yellow" xsi:type="CE">
                              <originalText>Colorless to Pale Yellow</originalText>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38304" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TOPICAL"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section>
               <id root="300b57b2-180f-1a18-e063-6394a90a03c0"/>
               <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
               <text>
                  <paragraph>
                     <content styleCode="bold">Rx Only</content>
                  </paragraph>
                  <paragraph>FOR TOPICAL USE ONLY 
  <br/>  NOT FOR OPHTHALMIC USE
 </paragraph>
               </text>
               <effectiveTime value="20170329"/>
            </section>
         </component>
         <component>
            <section>
               <id root="300b57b2-1810-1a18-e063-6394a90a03c0"/>
               <code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION"/>
               <title>DESCRIPTION</title>
               <text>
                  <paragraph>Metronidazole gel contains metronidazole, USP, at a concentration of 7.5 mg per gram (0.75%) in a gel consisting of carbomer 940, edetate disodium, methylparaben, propylene glycol, propylparaben, purified water, and sodium hydroxide. Metronidazole is classified therapeutically as an antiprotozoal and antibacterial agent. Chemically, metronidazole is named 2-methyl-5-nitro-1
 
  <content styleCode="italics">H</content>-imidazole-1-ethanol and has the following structure:

 </paragraph>
                  <renderMultiMedia referencedObject="MM1"/>
               </text>
               <effectiveTime value="20170329"/>
               <component>
                  <observationMedia ID="MM1">
                     <text>Chemical Structure</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="metronidazole-01.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="300b57b2-1811-1a18-e063-6394a90a03c0"/>
               <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>CLINICAL PHARMACOLOGY</title>
               <text>
                  <paragraph>Bioavailability studies on the topical administration of 1 gram of metronidazole gel (7.5 mg of metronidazole) to the face of 10 rosacea patients showed a maximum serum concentration of 66 nanograms per milliliter in one patient. This concentration is approximately 100 times less than concentrations afforded by a single 250 mg oral tablet. The serum metronidazole concentrations were below the detectable limits of the assay at the majority of time points in all patients. Three of the patients had no detectable serum concentrations of metronidazole at any time point. The mean dose of gel applied during clinical studies was 600 mg which represents 4.5 mg of metronidazole per application. Therefore, under normal usage levels, the formulation affords minimal serum concentrations of metronidazole. The mechanisms by which metronidazole gel acts in the treatment of rosacea are unknown, but appear to include an anti-inflammatory effect.</paragraph>
               </text>
               <effectiveTime value="20170329"/>
            </section>
         </component>
         <component>
            <section>
               <id root="300b57b2-1812-1a18-e063-6394a90a03c0"/>
               <code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>INDICATIONS AND USAGE</title>
               <text>
                  <paragraph>Metronidazole gel is indicated for topical application in the treatment of inflammatory papules and pustules of rosacea.</paragraph>
               </text>
               <effectiveTime value="20170329"/>
            </section>
         </component>
         <component>
            <section>
               <id root="300b57b2-1813-1a18-e063-6394a90a03c0"/>
               <code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="CONTRAINDICATIONS SECTION"/>
               <title>CONTRAINDICATIONS</title>
               <text>
                  <paragraph>Metronidazole gel is contraindicated in individuals with a history of hypersensitivity to metronidazole, parabens, or other ingredients of the formulation.</paragraph>
               </text>
               <effectiveTime value="20170329"/>
            </section>
         </component>
         <component>
            <section>
               <id root="300b57b2-1814-1a18-e063-6394a90a03c0"/>
               <code code="42232-9" codeSystem="2.16.840.1.113883.6.1" displayName="PRECAUTIONS SECTION"/>
               <title>PRECAUTIONS</title>
               <effectiveTime value="20170329"/>
               <component>
                  <section>
                     <id root="300b57b2-1815-1a18-e063-6394a90a03c0"/>
                     <code code="34072-9" codeSystem="2.16.840.1.113883.6.1" displayName="GENERAL PRECAUTIONS SECTION"/>
                     <title>General</title>
                     <text>
                        <paragraph>Metronidazole gel has been reported to cause tearing of the eyes. Therefore, contact with the eyes should be avoided. If a reaction suggesting local irritation occurs, patients should be directed to use the medication less frequently or discontinue use.</paragraph>
                        <paragraph>Metronidazole is a nitroimidazole and should be used with care in patients with evidence of, or history of blood dyscrasia.</paragraph>
                     </text>
                     <effectiveTime value="20170329"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="300b57b2-1816-1a18-e063-6394a90a03c0"/>
                     <code code="34076-0" codeSystem="2.16.840.1.113883.6.1" displayName="INFORMATION FOR PATIENTS SECTION"/>
                     <title>Information for patients</title>
                     <text>
                        <paragraph>This medication is to be used as directed by the physician. It is for external use only. Avoid contact with the eyes.</paragraph>
                     </text>
                     <effectiveTime value="20170329"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="300b57b2-1817-1a18-e063-6394a90a03c0"/>
                     <code code="34073-7" codeSystem="2.16.840.1.113883.6.1" displayName="DRUG INTERACTIONS SECTION"/>
                     <title>Drug interactions</title>
                     <text>
                        <paragraph>Oral metronidazole has been reported to potentiate the anticoagulant effect of coumarin and warfarin resulting in a prolongation of prothrombin time. The effect of topical metronidazole on prothrombin time is not known.</paragraph>
                     </text>
                     <effectiveTime value="20170329"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="300b57b2-1818-1a18-e063-6394a90a03c0"/>
                     <code code="34083-6" codeSystem="2.16.840.1.113883.6.1" displayName="CARCINOGENESIS &amp; MUTAGENESIS &amp; IMPAIRMENT OF FERTILITY SECTION"/>
                     <title>Carcinogenesis, mutagenesis, impairment of fertility</title>
                     <text>
                        <paragraph>Metronidazole has shown evidence of carcinogenic activity in a number of studies involving chronic, oral administration in mice and rats but not in studies involving hamsters.</paragraph>
                        <paragraph>Metronidazole has shown evidence of mutagenic activity in several
 
  <content styleCode="italics">in vitro</content>bacterial assay systems. In addition, a dose-response increase in the frequency of micronuclei was observed in mice after intraperitoneal injections and an increase in chromosome aberrations have been reported in patients with Crohn's disease who were treated with 200-1200 mg/day of metronidazole for 1 to 24 months. However, no excess chromosomal aberrations in circulating human lymphocytes have been observed in patients treated for 8 months.

 </paragraph>
                     </text>
                     <effectiveTime value="20170329"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="300b57b2-1819-1a18-e063-6394a90a03c0"/>
                     <code code="42228-7" codeSystem="2.16.840.1.113883.6.1" displayName="PREGNANCY SECTION"/>
                     <title>Pregnancy</title>
                     <effectiveTime value="20170329"/>
                     <component>
                        <section>
                           <id root="300b57b2-181a-1a18-e063-6394a90a03c0"/>
                           <code code="34077-8" codeSystem="2.16.840.1.113883.6.1" displayName="TERATOGENIC EFFECTS SECTION"/>
                           <title>Teratogenic effects</title>
                           <effectiveTime value="20170329"/>
                           <component>
                              <section>
                                 <id root="300b57b2-181b-1a18-e063-6394a90a03c0"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <title>Pregnancy category B</title>
                                 <text>
                                    <paragraph>There has been no experience to date with the use of metronidazole gel in pregnant patients. Metronidazole crosses the placental barrier and enters the fetal circulation rapidly. No fetotoxicity was observed after oral metronidazole in rats or mice. However, because animal reproduction studies are not always predictive of human response and since oral metronidazole has been shown to be a carcinogen in some rodents, this drug should be used during pregnancy only if clearly needed.</paragraph>
                                 </text>
                                 <effectiveTime value="20170329"/>
                              </section>
                           </component>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="300b57b2-181c-1a18-e063-6394a90a03c0"/>
                     <code code="34080-2" codeSystem="2.16.840.1.113883.6.1" displayName="NURSING MOTHERS SECTION"/>
                     <title>Nursing mothers</title>
                     <text>
                        <paragraph>After oral administration, metronidazole is secreted in breast milk in concentrations similar to those found in the plasma. Even though metronidazole gel blood levels are significantly lower than those achieved after oral metronidazole, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.</paragraph>
                     </text>
                     <effectiveTime value="20170329"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="300b57b2-181d-1a18-e063-6394a90a03c0"/>
                     <code code="34081-0" codeSystem="2.16.840.1.113883.6.1" displayName="PEDIATRIC USE SECTION"/>
                     <title>Pediatric use</title>
                     <text>
                        <paragraph>Safety and effectiveness in pediatric patients have not been established.</paragraph>
                     </text>
                     <effectiveTime value="20170329"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="300b57b2-181e-1a18-e063-6394a90a03c0"/>
               <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
               <title>ADVERSE REACTIONS</title>
               <text>
                  <paragraph>The following adverse experiences have been reported with the topical use of metronidazole: burning, skin irritation, dryness, transient redness, metallic taste, tingling or numbness of extremities and nausea.</paragraph>
               </text>
               <effectiveTime value="20170329"/>
            </section>
         </component>
         <component>
            <section>
               <id root="300b57b2-181f-1a18-e063-6394a90a03c0"/>
               <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>DOSAGE AND ADMINISTRATION</title>
               <text>
                  <paragraph>Apply and rub in a thin film of metronidazole gel twice daily, morning and evening, to entire affected areas after washing.</paragraph>
                  <paragraph>Areas to be treated should be cleansed before application of metronidazole gel. Patients may use cosmetics after application of metronidazole gel.</paragraph>
               </text>
               <effectiveTime value="20170329"/>
            </section>
         </component>
         <component>
            <section>
               <id root="300b57b2-1820-1a18-e063-6394a90a03c0"/>
               <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
               <title>HOW SUPPLIED</title>
               <text>
                  <paragraph>Metronidazole Gel USP, 0.75% is supplied in aluminum tubes containing:</paragraph>
                  <paragraph>5 g NDC 51672-4116-5 (physician sample, tube only) 
  <br/>  30 g NDC 51672-4116-2 
  <br/>  45 g NDC 51672-4116-6
 </paragraph>
               </text>
               <effectiveTime value="20170329"/>
               <component>
                  <section>
                     <id root="300b57b2-1821-1a18-e063-6394a90a03c0"/>
                     <code code="44425-7" codeSystem="2.16.840.1.113883.6.1" displayName="STORAGE AND HANDLING SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="bold">Store at 20°-25°C (68°-77°F)</content>[see USP Controlled Room Temperature].

 </paragraph>
                     </text>
                     <effectiveTime value="20170329"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="300b57b2-1822-1a18-e063-6394a90a03c0"/>
               <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
               <text>
                  <paragraph>Mfd. by: 
  <br/>  Taro Pharmaceutical Industries Ltd. 
  <br/>  Haifa Bay, Israel 26110
 </paragraph>
                  <paragraph>Dist. by: 
  <br/>
                     <content styleCode="bold">Taro Pharmaceuticals U.S.A., Inc.</content>
                     <br/>  Hawthorne, NY 10532

 </paragraph>
                  <paragraph>Revised: February, 2011</paragraph>
                  <paragraph>70684-0211-1 
  <br/>  449
 </paragraph>
               </text>
               <effectiveTime value="20170329"/>
            </section>
         </component>
         <component>
            <section>
               <id root="300b57b2-1823-1a18-e063-6394a90a03c0"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PRINCIPAL DISPLAY PANEL - 30 g Tube Carton</title>
               <text>
                  <paragraph>
                     <content styleCode="bold">NDC 51672-4116-2</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Metronidazole 
   <br/>  Gel USP, 0.75%
  </content>
                  </paragraph>
                  <paragraph>FOR TOPICAL USE ONLY. 
  <br/>  NOT FOR OPHTHALMIC USE.
 </paragraph>
                  <paragraph>
                     <content styleCode="bold">Keep this and all medications out of the reach of children.</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">30 g</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Rx only</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">TARO</content>
                  </paragraph>
                  <renderMultiMedia referencedObject="MM2"/>
               </text>
               <effectiveTime value="20170329"/>
               <component>
                  <observationMedia ID="MM2">
                     <text>PRINCIPAL DISPLAY PANEL - 30 g Tube Carton</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="metronidazole-02.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>